A genuinely late dose: what the labelling says and what people do — what changed since

A genuinely late dose: what the labelling says and what people do — what changed since — setting out what I have, and where I think it stops being reliable.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: semaglutide, 7 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 10 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

Pinch or no pinch: the decision depends on needle length and on your own anatomy. A longer needle (8 mm and up) reaches subcutaneous tissue easily without a pinch. A shorter needle (4-6 mm) is safer with a gentle pinch. The pinch size matters less than people think; the injection angle matters more.

What would change my mind on genuinely late dose is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.

Post #3 is right about the mechanism and I think understates the practical bit.

Injecting slowly is worth doing for volume rather than for chemistry. Larger volumes delivered quickly are the ones people report as uncomfortable.

I would not lead a decision with this, but I would not ignore it either.

No disagreement from me. Posting only so the question does not look ignored.

Needle length matters less than angle for subcutaneous delivery in most people. A short needle at ninety degrees and a longer one at forty-five put the material in roughly the same place.

It cost nothing to check and would have cost something not to.

Subcutaneous injection into abdominal tissue, thigh or upper arm is what the licensed labelling in this class describes, and the published comparisons found the differences in exposure between those sites small.

Leak-back after withdrawal: a small amount of liquid on the skin after withdrawal is ordinary. Whether you lost a "meaningful" dose depends on concentration and your target dose, but some leak-back is universal and does not need to be treated as an error.

A partial answer, offered because a partial answer beats none.

The arithmetic in post #7 is right; the assumption feeding it is the part to check.

A genuinely late dose: the labelling generally says that if the next dose is more than a couple of days away, take it as soon as you notice. If the next dose is close, skip it and resume the schedule. The reasoning follows from the long half-life; you are perturbing a slowly moving average.

I would want to see it done twice before believing it once.

Useful. I had the fact and not the reason, which turns out to be the important half.

Note the site alongside the dose. If a local reaction appears three weeks later you will want to know where the previous four injections went.

Post #10 put the caveat in the right place and I want to underline it.

A site rotation scheme that actually works: abdomen, outer thigh, back of arm, outer hip. Rotate through them in order, move a minimum 2 cm between consecutive sites, note the site with each dose. If a local reaction appears you have the history. If you rotate properly you will not get lipohypertrophy from overuse of one area.

I have changed my mind on this once already, so take it as current rather than settled.